Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myeloid, Acute 1Carcinoma, Small Cell 1Burkitt Lymphoma 1

Interventions

Cisplatin 5Etoposide 4Pemetrexed 3Carboplatin 3pembrolizumab 2belinostat 2RRx-001 2vosaroxin 1taxane 1sagopilone 1pomalidomide 1lurtotecan 1liposomal doxorubicin 1etoposide phosphate 1enzalutamide 1atezolizumab 1abiraterone 1Vinorelbine 1Rhenium 1Radiation 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1PT-100 dipeptide 1PM 01183 1Molecular Diagnostic Techniques 1Irinotecan 1Immunotherapy 1Gemcitabine 1GSK2879552 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Small Cell × BI 2536 × Clear all
NCT00412880 2022-06-22

BI 2536 Second Line Monotherapy in SCLC

Boehringer Ingelheim

Phase 2 Completed
23 enrolled 10 charts

Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡